Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics Inc. is strategically positioned in the biopharmaceutical sector, focusing on developing TH103, which exhibits promising preclinical results indicating superior retinal retention and potential for longer-lasting anti-VEGF activity compared to existing therapies like Eylea and Vabysmo. The impressive market performance of anti-VEGF drugs, exemplified by Vabysmo's $4 billion in sales within three years, highlights the significant financial opportunities for innovative products that can provide incremental improvements in treatment options. Additionally, the complete inhibition of VEGF-induced endothelial cell proliferation observed in TH103's preclinical trials suggests that it may achieve substantial clinical efficacy, reinforcing the positive outlook for Kalaris Therapeutics's stock based on its development trajectory and market potential.

Bears say

Kalaris Therapeutics Inc is a clinical-stage biotechnology company that has yet to establish any revenue-generating products, relying heavily on the development of its anti-VEGF drug, TH103. The company faces substantial financial risks as it will likely continue to incur significant net losses through commercialization and into the early launch phase, necessitating the establishment of a robust infrastructure for successful product marketing. Furthermore, competition from both existing and emerging therapies poses additional risks that could hinder market penetration, alongside potential delays in clinical development and regulatory approvals that may lead to increased costs and extended timelines.

Allovir Inc (KLRS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Allovir Inc (KLRS) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.